TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Up 0.7 %

Shares of TherapeuticsMD stock opened at $1.42 on Wednesday. The business’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $1.74. TherapeuticsMD has a 52 week low of $1.15 and a 52 week high of $2.84.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.